The therapeutic effect of glucocorticoids on type II respiratory failure, heart failure, and massive pericardial effusion caused by hypothyroidism: A case report

Jingyue Wang, Xiangjun Li, Botao Shen, Shipeng Wang, Jiahuan He and Yushi Wang*

Department of Cardiology, The First Hospital of Jilin University, Changchun, China

Background: Hypothyroidism is a disease commonly observed in outpatient clinics but can occasionally cause severe cardiovascular and respiratory diseases requiring hospitalization.

Case report: The patient reported herein suffered from heart failure, massive pericardial effusion, type II respiratory failure, and hypothyroidism. There was no related basic diseases of respiratory and cardiovascular system in the past. She failed to be weaned from invasive ventilation multiple times after routine treatment and was finally successfully weaned on day five of receiving the combination therapy of a high-dose methylprednisolone intravenous drip and levothyroxine oral administration.

Conclusion: This case report indicates that hypothyroidism may be a cause of type II respiratory failure, heart failure, and massive pericardial effusion without cardiac tamponade and that a combination of levothyroxine and corticosteroids could effectively treat the disease. Clinical workers should consider the role of thyroid function in diagnosis, and the admission team should include this aspect in the monitoring scope. Moreover, the role of hormones in the treatment of patients with severe hypothyroidism should not be ignored, and timely treatment should be provided.

KEYWORDS
hypothyroidism, heart failure, glucocorticoids, type II respiratory failure, dyspnea, invasive ventilator assisted ventilation, severe case report
Introduction

Hypothyroidism is defined as insufficient secretion or inadequate function of thyroid hormone in the target tissue. It is commonly observed in outpatient settings and seldom requires hospitalization. However, rarely, the disease can affect the metabolism of multiple organ systems and lead to dysfunction; such cases are primarily divided into two categories as follows: 1) primary hypothyroidism; 2) secondary hypothyroidism, e.g., central thyrotropin-releasing hormone or thyroid-stimulating hormone deficiency, or consumptive hypothyroidism caused by excessive thyroid hormone inactivation. In most patients, the oral administration of exogenous synthetic thyroid hormone can significantly relieve the disease (Almandoz and Gharib, 2012).

The current case report describes the case of an older woman with heart failure, type II respiratory failure, and massive pericardial effusion caused by hypothyroidism in a cardiac intensive care unit (CICU). It discusses her clinical manifestations, diagnosis, and treatment, shares experiences related to her diagnosis, treatment, and weaning difficulties, and presents conclusions on glucocorticoids therapy, based on the results.

Case presentation

The patient was a 64-year-old woman who had intermittent dyspnea with edema in both lower limbs for 15 days. Prior to this, she had been physically healthy, and she had no family history of related genetic diseases and no recorded history of smoking or alcohol consumption. Her mother died of a heart attack. The patient was given a primary diagnosis of heart failure, type II respiratory failure, and massive pericardial effusion caused by hypothyroidism (Almandoz and Gharib, 2012). The patient was given levothyroxine 25 ug orally once daily (QD). The overall treatment protocol was as follows. This patient began taking levothyroxine orally (25 ug, QD) after admission. On day six of admission, the dose was adjusted to 50 ug QD; on day nine after admission, the patient had dyspnea and sweating 10 min after the weaning test and had to maintain the original ventilator mode and parameters. On day three of methylprednisolone treatment (day nine after admission), the patient had dyspnea and arterial hypotension. At 12:30, the patient was vaguely conscious and still had dyspnea. An urgent blood gas analysis showed that the carbon dioxide partial pressure could not be measured.

Thus, the anesthesiology department was contacted for emergency endotracheal intubation and the patient was given invasive ventilator auxiliary support treatment. At 12:40, the patient’s BP was 140/60 mmHg, and her HR was 68 bpm; any changes in her condition were closely observed. According to the consultation opinion of the chief physician of the endocrinology department, methylprednisolone (80 mg, QD) was given on the same day. On day three of methylprednisolone treatment (day nine after admission), the patient had dyspnea and arterial hypotension. At 12:30, the patient was vaguely conscious and still had dyspnea. An urgent blood gas analysis showed that the carbon dioxide partial pressure could not be measured. Therefore, the anesthesiology department was contacted for emergency endotracheal intubation and the patient was given invasive ventilator auxiliary support treatment. At 12:40, the patient’s BP was 140/60 mmHg, and her HR was 68 bpm; any changes in her condition were closely observed. According to the consultation opinion of the chief physician of the endocrinology department, methylprednisolone (80 mg, QD) was given on the same day. On day three of methylprednisolone treatment (day nine after admission), the patient had dyspnea and arterial hypotension. At 12:30, the patient was vaguely conscious and still had dyspnea. An urgent blood gas analysis showed that the carbon dioxide partial pressure could not be measured.
TABLE 1 The patient’s laboratory data.

| Parameter    | Values   | References value | Unit   |
|--------------|----------|------------------|--------|
| PH           | 7.22     | 7.35–7.45        |        |
| Lac          | 0.6      | 0.5–2.2          | mmol/L |
| HCO3⁻        | 43.0     | 18.0–23.0        | mmol/L |
| BE           | 15.3     | –2.0–3.0         | mmol/L |
| PCO₂         | 105      | 35–48            | mmHg   |
| PO₂          | 46       | 83–108           |        |
| WBC          | 10.02    | 3.5–9.5          |        |
| NE           | 0.86     | 0.40–0.75        | %      |
| NE#          | 8.57     | 1.80–6.30        |        |
| Hb           | 127      | 115–150          | g/L    |
| PLT          | 209      | 125–350          | U/L    |
| CK            | 1050     | 40–200           | U/L    |
| CKMB         | 36.5     | 0.0–25.0         | U/L    |
| Mb           | 140      | 0–107            | ng/ml  |
| Tn           | <0.05    | 0–0.05           | ng/ml  |
| BNP          | 361      | 0–100            | pg/ml  |
| D-dimer      | 348      | 100–600          |        |
| h-HBDDH      | 306      | 72–182           | U/L    |
| LDH          | 434      | 120–250          | U/L    |
| PCT          | 0.27     | 0.00–0.50        | ng/ml  |
| TSH          | 11.078   | 0.35–4.94        | mU/ml  |
| FT3          | <1.64    | 2.43–6.01        | pmol/L |
| FT4          | <5.15    | 9.01–19.05       | pmol/L |
| A-TgPO       | 791.9    | 0.5–5.61         | IU/ml  |
| A-Tg         | >10000.00| 0.4–4.11         | pmol/L |
| E2           | 39.60    | <59.45–241       | pmol/L |
| P4           | 0.84     | <0.54–1.08       | pmol/L |
| PRL          | 183.10   | 117.68–505.7     | mIU/L  |
| FSH          | 30.63    | 11.9–108.7       | mIU/ml |
| TE           | <0.17    | <0.56–1.77       | mIU/ml |
| LH           | 7.58     | 15.4–53.3        | mIU/ml |
| Cor          | 472.92   | <276.0           | U/L    |
| AST           | 35.0     | 13.0–35.0        | U/L    |
| ALT          | 15.2     | 7.0–40.0         | U/L    |
| TB            | 9.3      | 0.0–21.0         | umol/L |
| DBIL         | 1.8      | 0.0–6.8          | umol/L |
| IBIL         | 7.5      | 5.0–20.0         | umol/L |
| BUN          | 5.18     | 3.1–8.8          | umol/L |
| sCr          | 58.3     | 41–81            | umol/L |
| UA           | 401      | 150–360          | mg/dL  |
| hs-CRP       | 15.63    | 0–3.5            | pmol/L |
| ACTH         | 6.75     | 1.6–13.9         |        |
| TC           | 6.13     | 2.6–6.0          | mmol/L |
| TG           | 1.25     | 0.28–1.80        | mmol/L |
| HDL          | 2.07     | 0.76–2.10        | mmol/L |
| LDL          | 3.29     | 2.06–3.10        | mmol/L |
| AMA-M2       | 110.1    | 0–20             | units  |

Lac, lactic acid; BE, base excess; WBC, white blood cell; NE, neutrophils; PLT, platelets; Hb, hemoglobin; CKMB, creatine kinase MB; Mb, myoglobin; Tn, troponin; BNP, brain natriuretic peptide; h-HBDDH, alpha-hydroxybutyrate dehydrogenase; LDH, lactate dehydrogenase; PCT, procalcitonin; TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; A-TPO, thyroid peroxidase antibody; A-Tg, thyroglobulin antibodies; E2, estradiol; P4, progesterone; PRL, prolactin; FSH, follicle-stimulating hormone; TE, testosterone; LH, luteinizing hormone; Cor, cortisol; AST, aspartate aminotransferase; ALT, alanine transaminase; TB, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; BUN, blood urea nitrogen; sCr, serum creatinine; UA, uric acid; hs-CRP, high-sensitivity C-reactive protein; ACTH, adrenocorticotropic hormone; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AMA-M2, anti-mitochondrial M2 antibody.

Discussion and review of the literature

Thyroid hormone affects the functioning of nearly all of the body’s organs. Hypothyroidism can lead to metabolic disorders and organ diseases but generally does not require hospitalization. The case reported herein concerned severe hypothyroidism with heart failure, type II respiratory failure, and severe pericardial effusion, which are all critical conditions. The patient had to be admitted to the CICU for invasive ventilation, to receive high doses of steroid hormone, standard doses of thyroid hormone, and other treatments.

The effects of thyroid hormone deficiency on the body’s organs

The authors conducted a literature search and found that kidney damage and hypothyroidism could impact one another.
Respiratory failure (Finsterer et al., 2002; Fukusumi et al., 2014), heart disease (Udovcic et al., 2017; Rastogi et al., 2018), facial paralysis and pituitary hyperplasia (Han et al., 2012; Sharma et al., 2020), as well as myopathy (Lin et al., 2020), can also be caused by hypothyroidism. The clinical features of cases of severe hypothyroidism are summarized in Table 3. Currently, there are few reports on simultaneous respiratory failure, heart failure, and acute disease.

The relationship between respiratory failure, heart failure, and hypothyroidism

Type II respiratory failure, also known as hypercapnic respiratory failure, refers to the inability of the respiratory system to oxygenate and expel carbon dioxide (Phoung and Virginia, 2014). Common pathogenies include airway obstruction, kyphosis, and other restrictive pulmonary ventilation disorders, congenital or traumatic chest-wall deformities (e.g., flail chest), neuromuscular
diseases (e.g., phrenic paralysis, myopathy, and muscular dystrophy), and diaphragm disorders (e.g., paralysis and congenital diaphragmatic hernia) (Lin et al., 2020). Hypothyroidism, as a cause of type II respiratory failure, is rarely encountered in clinical practice and can easily be overlooked. According to previous researches, the pathophysiological mechanisms of this condition

| Testing time       | AO (mm) | LAD (mm) | LVEDD (mm) | LVPW (mm) | RVD (mm) | CO (L/min) | LVEF (%) | SV (ml) | E/A  | Diastolic fluid level width of pericardial effusion |
|--------------------|---------|----------|------------|-----------|----------|------------|----------|---------|------|---------------------------------|
| On admission       | 32      | 34       | 44         | 11        | 24       | 3.5        | 41       | 46      | 51/72 (0.71) | Posterior wall of left ventricle 22 mm |
| D5 after admission | 34      | 36       | 48         | 11        | 26       | 2.7        | 50       | 47      | 74/47 (1.57) | Posterior wall of left ventricle 3 mm |
| D20 after admission| 34      | 36       | 49         | 11        | 24       | 4.8        | 54       | 60      | 72/92 (0.78) | Posterior wall of left ventricle 3 mm |

AO, aorta; LAD, left atrial anteroposterior diameter; LVEDD, left ventricular end diastolic diameter; LVPW, left ventricular posterior wall; RVD, right ventricular anteroposterior diameter; CO, cardiac output; LVEF, left ventricular ejection fraction; SV, stroke volume; E/A, ratio of E to A.

**TABLE 2 The dynamic evolution of UCG.**

**FIGURE 2**
The red arrow represents the start of the use of glucocorticoids. The green arrow represents the levothyroxine administration. The numbered green arrows indicate the administered doses as follows: 1, 25 mg/d; 2, 50 mg/d; 3, 100 mg/d; 4, 125 mg/d. The following are also shown: (A) thyroid-stimulating hormone, free triiodothyronine, and free thyroxine; (B) thyroid peroxidase antibody and thyroglobulin antibodies; (C) PO2, FiO2, and oxygenation index; (D) white blood cell count and NE%.
| Case (ref.) | Age (year)/Sex | Initial presentation | Physical examination | Involved organ | Treatment | Prognosis |
|------------|----------------|---------------------|---------------------|---------------|-----------|-----------|
| 1) Liakopoulos et al. (2009) | 28/F | constipation | paleness of skin; nonpitting edema of lower extremities; no goiter; acute renal failure | thyroid hormone substitution | after 2 years of follow-up: renal function remains normal |
| 2) Fukusumi et al. (2014) | 70/M | easy fatigability | GCS: 6; no goiter or thyroid bruit; unresponsive; respiratory failure | oral levothyroxine, under steroid cover, mechanical ventilation | 6 years later: continuously dependent on NIPPV |
| 3) Rastogi et al. (2018) | 30/F | decreased appetite, progressive shortness of breath on exertion, swelling all over body for 6 months | tachypneic; normotensive, and afebrile; DCM | thyroid hormone replacement therapy, conventional therapy for DCM | during the course of treatment, her LV function and clinical symptoms improved |
| 4) Han et al. (2012) | 15 patients: average 24/6 M 9F | acratia, aversion to cold, anorexia, facial edema; pretibial myxedema; hypoevolutism | not applicable | pituitary tumorous hyperplasia; substitute therapy (L-T4, plasma T3, T4, TSH, PRL) | after 4–11 months of substitute therapy: the enlarged pituitary returned to normal size |
| 5) Lin et al. (2020) | 65/M | 5-year history of gradually progressive dyspnea and pedal edema | distant heart sounds; massive pericardial effusion with tamponade and an EF of 20%–25% | thyroxin replacement therapy | after 3 months follow-up: echocardiography was normal |

F, female; M, male; LV, left ventricle; GSC, glasgow coma scale; NIPPV, noninvasive positive pressure ventilation; DCM, dilated cardiomyopathy; EF, ejection fraction.
are as follows: slow metabolism; respiratory muscle weakness; diaphragm dyskinesia; a slow respiratory rate and decreased ventilation function; a decreased driving ability of the respiratory center and decreased response to high carbon dioxide and hypoxic stimulation; edema of the tongue, nasal mucosa, and larynx, which exerts pressure on the respiratory tract, causes sleep apnea syndrome, and aggravates dyspnea and hypoxia. Pulmonary interstitial and alveolar edema decrease pulmonary compliance, ventilation function, and alveolar diffusion function, and cause a pulmonary ventilation/ blood-flow-ratio imbalance, which is further complicated by heart disease and infection (Jain et al., 1973; Siafakas et al., 1992; Siafakas and Bouros, 1993; Behnia et al., 2000).

The exact pathogenesis of heart disease caused by hypothyroidism remains unclear. Some studies have shown that hypothyroidism can lead to atherosclerosis by accelerating vascular endothelial dysfunction (Cappola and Ladenson, 2003). This may also be related to the high concentration of low-density lipoprotein cholesterol that results from hypothyroidism (Mayer et al., 2006). Therefore, thyroid hormone should also be monitored by admission teams in the cardiology and respiratory departments to reduce the rate of missed diagnoses.

### Factors impacting weaning

Acidosis and changes in mental state are common reasons to induce mechanical ventilation in patients with severe hypothyroidism (Behnia et al., 2000). Whether a patient can wean primarily depends on three factors, i.e., the improvement of the primary disease, the amount of available sputum and the patient’s ability to cough up sputum, and the patient’s state of consciousness (Shaikh et al., 2014). Existing studies have shown that the condition of patients with hypoxemia and hypercapnia can be effectively improved by treatment with levothyroxine for 7–10 days (Ladenson et al., 1988; Behnia et al., 2000). In the current case, the weaning failed on day four and seven of levothyroxine but was successful on day five of methylprednisolone combined with levothyroxine.

Thyroid hormone plays a crucial role in the body’s water–sodium balance and hemodynamics (Capasso et al., 1999). Traditionally, glucocorticoids can cause fluid and sodium retention and, given this, patients with heart failure should not use these drugs (or use it with caution). Current evidence suggests, however, that the short-term use of corticosteroids in patients with heart failure is safe and can improve loop diuretic resistance (Liu and Liu, 2014). Some animal experiments have shown that glucocorticoids can, specifically, dilate renal blood vessels, regulate the synthesis and release of atrial natriuretic peptides, and up-regulate atrial natriuretic peptide receptors on vascular endothelial cells, thereby realizing strong diuretic and natriuretic effects (Liu et al., 2006). A small clinical study showed that prednisone had a strong diuretic effect on patients with heart failure, and may be able to improve renal function (Liu et al., 2006). However, a larger randomized and double-blind controlled study is still needed for further clarification in this regard.

Glucocorticoids are endogenous adrenocorticoids (Magiakou et al., 2006) that can stimulate the differentiation and functional development of the lungs (Busada and Cidlowski, 2017) and effectively inhibit the activation of the immune and inflammatory systems (Barnes and Adcock, 2003). It is an effective anti-inflammatory drug for the treatment of respiratory diseases (Adcock and Mumby, 2017a). Although the level of serum cortisol in the patient in the current case was higher than normal (primarily the result of disease stress), the authors nonetheless decided to intervene with high-dose glucocorticoid treatment, considering the consultation opinions of the endocrinology department.

In the lungs, the glucocorticoid receptor (GR) plays a crucial role in bronchoconstriction, micro-vasoconstriction, immune surveillance maintenance, and alveoli patency (Barnes, 2004; Adcock and Mumby, 2017b). Leseney et al. (1987) demonstrated that, in vitro, low thyroid hormone levels could inhibit the expression of the GR, causing hormone resistance. The increase of the serum thyroid hormone level after thyroid hormone replacement therapy will increase the expression of the GR, enhance the combination of the GR and glucocorticoids, and, finally, enhance the efficacy of glucocorticoids. In the current case, after continuous diuretic treatment, the patient still failed to wean until glucocorticoid administration. The current case report results further supported the therapeutic effect of glucocorticoids combined with thyroid hormone in respiratory failure caused by severe hypothyroidism.

### Conclusion

According to the specific conditions of the patients, clinical workers should consider the role of thyroid function in diagnosis, and the admission team might need to include this aspect in the monitoring scope. For patients with severe hypothyroidism, glucocorticoids treatment may be needed, particularly if weaning difficulties occur. The early application of levothyroxine is a key intervention in the treatment of these patients.

### Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement

The studies involving human participants were reviewed and approved by First Hospital of Jilin University ethics committee. The ethics committee waived the requirement of written informed consent for participation. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

JW conceived the idea and conceptualized the case. SW and JH collected the data. XL and BS analyzed the data. JW drafted the manuscript. YW reviewed the manuscript. All authors read and approved the final draft.

References

Adcock, I. M., and Mambey, S. (2017). *Handb. Exp. Pharmacol.* 237, 171–196. doi:10.1007/164_2016_98

Almandou, J. F., and Garth, H. (2012). Hypothyroidism: Etiology, diagnosis, and management. *Med. Clin. North Am.* 96 (2), 203–221. doi:10.1016/j.mcna.2012.01.005

Barnes, P. J., and Adcock, I. M. (2003). How do corticosteroids work in asthma? *Ann. Intern. Med.* 139 (5), 359–370. doi:10.7326/0003-4819-139-5-part_1-20030920-00012

Barnes, P. J. (2004). Distribution of receptor targets in the lung. *Proc. Am. Thorac. Soc.* 1 (4), 345. doi:10.1513/pats.200409-045MS

Behnia, M., Clay, A. S., and Farber, M. O. (2000). Management of myxedematous respiratory failure: Review of ventilation and weaning principles. *Am. J. Med. Sci.* 320 (6), 368–373. doi:10.1097/00003844-200012000-00003

Busada, J. T., and Călățoiu, I. A. (2017). Mechanisms of glucocorticoid action during development. *Curr. Top. Dev. Biol.* 125, 147–170. doi:10.1016/bse.tdb.2016.12.004

Capasso, G., De Tommaso, G., Pica, A., Anastasio, P., Capasso, J., Kunne, R., et al. (1999). Effects of thyroid hormones on heart and kidney functions. *Min. Electrolyte Metab.* 25 (1-2), 56–64. doi:10.1590/S0057-424119990001-00003

Cappola, A. R., and Ladenson, P. W. (2003). Hypothyroidism and atherosclerosis. *J. Clin. Endocrinol. Metab.* 88 (6), 2438–2444. doi:10.1210/jc.2003-030398

Finsterer, J., Prainer, C., Stollberger, C., Valentin, A., Jarius, C., and Schreier, R. (2002). Hypothyroidism and muscular respiratory failure successfully treated with levothyroxine. *South. Med. J.* 95 (11), 1347–1349. doi:10.1097/00007611-200211000-00023

Fukusumi, M., Isada, T., Mouri, A., Hamamoto, Y., and Kamimura, M. (2014). Respiratory failure associated with hypoventilation in a patient with severe hypothyroidism. *Respirol. Case Rep.* 2 (2), 79–80. doi:10.1111/rcr.12342-0

Han, L., Wang, J., Shu, K., and Lei, T. (2012). Piratinty tumorous hyperplasia due to primary hypothyroidism. *Acta Neurochir.* 154 (8), 1489–1492. doi:10.1007/s00701-012-1422-0

Jain, B. P., Brody, J. S., and Fisher, A. B. (1973). The small lung of hypopituitarism. *J. Clin. Endocrinol. Metab.* 37 (4), 877–883. doi:10.1210/jcem-37-4-877

Lesenyi, A. M., Bennmilad, M., Befort, N., and Befort, J. J. (1987). In vitro evidence that hypothyroidism modifies glucocorticoid receptors. *Mol. Cell. Endocrinol.* 52 (1-2), 1–10. doi:10.1016/0303-7207(87)90090-6

Liangopoulos, V., Davos, S., Simopoulos, T., Zarogiannis, S., Giannopoulou, M., Kourti, P., et al. (2009). Acute renal failure: A rare presentation of hypothyroidism. *Res. Fail.* 31 (4), 323–326. doi:10.1086/59029780127

Lin, N., Wang, J., Liao, W., and Wen, Y. (2020). Hypothyroid myopathy with periodic paralysis as the main symptom: A case report and literature review. *Ann. Palliat. Med.* 9 (5), 3689–3704. doi:10.21037/apm-20-1578

Liu, C., Chen, H., Zhou, C., Ji, Z., Liu, G., Gao, Y., et al. (2006). Potent potentiating diuretic effects of prednisone in congestive heart failure. *J. Cardiovasc. Pharmacol.* 48 (4), 173–176. doi:10.1097/01.fjc.0000245242.57088.5b

Liu, C., and Liu, K. (2014). Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. *J. Card. Fail.* 20 (9), 625–629. doi:10.1016/j.cardfail.2014.06.033

Magiakou, M. A., Smyrnaki, P., and Chrousos, G. P. (2006). Hypertension in Cushing’s syndrome. *Rest. Pract. Res. Clin. Endocrinol. Metab.* 20 (3), 467–482. doi:10.1016/j.beem.2006.07.006

Mayer, O., Jr. Simon, J., Filipovský, J., Plásková, M., and Pikner, R. (2006). Hypothyroidism in coronary heart disease and its relation to selected risk factors. *Vasc. Health Risk Manag.* 2 (4), 499–506. doi:10.2147/vhrm.2006.2.4.499

Montasser, D. I., Hassani, M., Zajiči, V., Bahadi, A., Alayoud, A., Hamzi, A., et al. (2010). [Clinical case of acute renal failure revealing an autoimmune hypothyroidism]. *Nephrol. Ther.* 6 (2), 128–131. doi:10.1016/j.nephrol.2009.12.005

Phoung, V., and Virginina, S. K. (2014). Respiratory failure. *Pediatr. Rev.* 35, 476–484. doi:10.1542/pir.35-11-476

Rastogi, P., Dua, A., Attri, S., and Sharma, H. (2018). Hypothyroidism-induced reversible dilated cardiomyopathy? *J. Postgrad. Med.* 64 (5), 177–179. doi:10.4103/jrpm.JRMP-20-1578

Shaihk, H., Morales, D., and Laghi, F. (2014). Weaning from mechanical ventilation. *Semin. Respir. Crit. Care Med.* 35 (4), 451–468. doi:10.1055/s-0034-1381953

Sharma, A., Noor, N., and Dudhwal, V. (2020). Neurological manifestation in severe hypothyroidism in pregnancy. *BMJ Case Rep.* 13 (12), e238069. doi:10.1136/bcr-2020-238069

Siafakas, N. M., and Bourou, D. (1993). Respiratory muscles in endocrinopathies. *Respir. Med.* 87 (5), 351–358. doi:10.1016/0954-6111(93)90848-5

Siafakas, N. M., Salesiotou, V., Filaditaki, V., Tzanakis, N., Thalassinos, N., and Bonaros, D. (1992). Respiratory muscle strength in hypothyroidism. *Chest* 102 (1), 189–194. doi:10.1378/chest.102.1.189

Udovcin, M., Pena, R. H., Patham, B., Tabatabai, L., and Kansaara, A. (2017). Hypothyroidism and the heart. *Methodist Debakey Cardiovasc. J.* 13 (2), 55–59. doi:10.14797/mdcj-13-2-55

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.